Artificial intelligence in a primary care and clinic settings increases the likelihood of catching diabetic retinopathy in underinsured patients, resulting in increased successful referrals.
Insulin pumps, digital technology and outcome analyses are useful tools
Despite setbacks in DME, Adverum Biotechnologies said it will continue to develop ADVM-022 for wet AMD.
A multifaceted evaluation that includes ultra-widefield imaging can reveal new information and influence treatment decisions.
OPT-302 in combination with standard-of-care anti-VEGF-A agents shown to improve visual acuity, anatomic endpoints.
David A. Eichenbaum, MD, FASRS and Caroline Baumal, MD provide take-home messages to providers treating AMD and DME.
Retinal imaging tests are providing material to train and test decision support systems.
New opportunities continue to develop in an evolving landscape.
Promoting Tie2 signaling activity may complement inhibition of VEGF in addressing pathology in disease states characterized by angiogenesis, vascular permeability, and inflammation.
Key takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.
In the 30 years since optical coherence tomography was first described, it has become one of the most widely used technologies for imaging the human eye.
In response to a previously published article, three ophthalmologists present their views on intravitreal pharmacotherapy injections.
In the 30 years since optical coherence tomography was first described, it has become one of the most widely used technologies for imaging the human eye.
Being able to visualize and evaluate the retinal periphery provides a better understanding of the disease status and supports a better treatment decision.
As we approach the end of 2022, members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.
Evidence-based medicine can lead to personalized care, better results for patients
A window into the world of academic retina practice today.
In the 30 years since optical coherence tomography was first described, it has become one of the most widely used technologies for imaging the human eye.
Dr. Ramin Tadayoni discusses the myopia panel at the EURETINA 2021 virtual meeting.
A multifaceted evaluation that includes ultra-widefield imaging can reveal new information and influence treatment decisions.
How long-term intravitreal steroid technology fits into a modern clinic.
Minimizing clinic visits, maximizing use of imaging modalities are key
Although off-label repackaged bevacizumab syringes appear to satisfy an urgent clinical and financial need for patients with a variety of retinal disorders, they are known to be associated with considerable public health concerns due to the risks posed to patients from compounding pharmacies’ lack of compliance with a variety of FDA requirements.
In response to a previously published article, three ophthalmologists present their views on intravitreal pharmacotherapy injections.
Technology that allows consistent monitoring could be useful tools in 2022—and may be the key to tracking nAMD progression in fellow eyes among patients who have had intervals extended due to new technology.
A retina specialist discusses impressions and key take away points from patient case.